The global rare neurodegenerative disease treatment market is anticipated to grow at a considerable CAGR of 68% during the forecast period (2022-2028). All the market players of drug manufacturing company are involved in strategic alliances like acquisitions, partnership and collaboration along with research and development to launch new products to hold their position in the global market. Recently, EPSEN Pharma and Exicure Inc. have signed an exclusive agreement to research, develop and commercialize Spherical Nucleic acid as potential investigation treatment for neurodegenerative disease. Similarly, Biogen had made a strategic partnership with F. Hoffmann – La Roche Ltd. in 2019, to ensure robust distribution of drugs and launched two new drugs named Madopar and Ocruves.
Browse the full report description of “Global Rare Neurodegenerative Disease Treatment Market Size, Share & Trends Analysis Report by Indications (Parkinson’s Disease, Amyotrophic Lateral Sclerosis, Alzheimer’s Disease, Multiple Sclerosis, Spinal Muscular Atrophy, Huntington Disease, and Other Indications), by Drug Class (Immunomodulator Drugs, Cholinesterase Inhibitors, Dopamine Agonists, N-methyl-D-Aspartate Receptor Antagonists, and Others) Forecast 2022-2028” at https://www.omrglobal.com/industry-reports/rare-neurodegenerative-disease-treatment-market
Moreover, Aduhelm had received FDA approval to treat patient with Neurodegenerative disease in August 2021. This drug also helps to cure Alzheimer’s disease. Recently, in June 2021, the FDA approved Biogen’s Alzheimer’s disease drug aducanumab. This is the first medication cleared by US regulators and first Alzheimer’s disease treatment drug.
Market Coverage
• The market number available for – 2022-2028
• Base year- 2022
• Forecast period- 2022-2028
• Segment Covered-
o By Indications
o By Drug Type
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- Allergan plc. , Bayer AG, GlaxoSmithKline plc. , Johnson & Johnson Services Inc., Merck & Co. Inc. and others
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Rare Neurodegenerative Disease Treatment Market Report Segment
By Indications
• Parkinson’s Disease
• Amyotrophic Lateral Sclerosis
• Alzheimer’s Disease
• Multiple Sclerosis
• Spinal Muscular Atrophy (SMA)
• Huntington Disease Other Indications
By Drug Class
• Immunomodulator DrugCholinesterase Inhibitors
• Dopamine Agonists
• N-methyl-D-aspartate Receptor Antagonists
• Others
Global Rare Neurodegenerative Disease Treatment Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/rare-neurodegenerative-disease-treatment-market